• / Free eNewsletters & Magazine
  • / My Account
Home>Biogen, AbbVie's Once-Monthly MS Injection Approved in U.S.

Biogen, AbbVie's Once-Monthly MS Injection Approved in U.S.

3party Content

Sat, 28 May 2016

By George Stahl U.S. regulators approved the once-monthly, self-administered injection to treat multiple sclerosis made by Biogen Inc. and AbbVie Inc., but with a warning about the drug causing possible liver damage. Biogen and AbbVie are co-promoting daclizumab in the U.S. Pricing information for
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.